Is there a relationship between dopamine and rhegmatogenous retinal detachment?

Martucci, Alessio; Cesareo, Massimo; Pinazo-Durán, María Dolores; Pierro, Michela Di; Marino, Matteo Di; Nucci, Carlo Alberto; Coletta, Massimo; Mancino, Raffaele

doi:10.4103/1673-5374.265559

Cited by 7 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study reported a case report of focal visual area defects that occurred due to macular neuroretinopathy after nasal cocaine intake (14) . Dopamine, which is the basic neurotransmitter in developing addiction, also has roles in vision signals and in ensuring the light adaptation in visual pathways (15) . It has been shown that the loss of dopamine is associated with the thinning of the macular layer (16) .…”

Section: Discussionmentioning

confidence: 99%

Relationship between optical coherence tomography findings and clinical variables in patients with opiate use disorder

Özsoy¹,

Kulu²,

Özarslan³

et al. 2023

ABO

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Relationship between optical coherence tomography findings and clinical variables in patients with opiate use disorder

Özsoy¹,

Kulu²,

Özarslan³

et al. 2023

ABO

View full text Add to dashboard Cite

show abstract

“…Acting via dopamine D2-like receptors such as D4Rs in PR cells, DA modulates the production of cyclic adenosine monophosphate (cAMP), downregulating melatonin synthesis [ 287 ], and regulating the cell to cell coupling among horizontal cells depending on the phase of the light cycle [ 288 ]. Dopamine has also been revealed to act as a chemical messenger in trophic functions of the retina [ 289 , 290 ]. Although dopamine has been reported to have either protective or toxic roles on neurons (most likely due to the malfunctioning mechanisms regulating dopamine homeostasis) [ 291 ], yet it is one of the few neuroprotective factors applied in humans.…”

Section: Current Approaches Of Photoreceptor Regenerationmentioning

confidence: 99%

“…Although dopamine has been reported to have either protective or toxic roles on neurons (most likely due to the malfunctioning mechanisms regulating dopamine homeostasis) [291], yet it is one of the few neuroprotective factors applied in humans. Levodopa, also known as L-Dopa and l-3,4-dihydroxyphenylalanine, has been effective on the patient with AMD [199,203], contrast sensitivity [292], visual alterations in de novo Parkinson's disease [293], ischemic and traumatic optic neuropathies [294][295][296], and rhegmatogenous retinal detachment [289]. However, to translate treatments targeting dopamine to the clinic, systemic side effects observed in Parkinson's patients, like insomnia, gastrointestinal symptoms, motor side effects and hallucinations need to be considered [297][298][299].…”

Section: Synthetic Bile Acidmentioning

confidence: 99%

Potential therapeutic strategies for photoreceptor degeneration: the path to restore vision

et al. 2022

View full text Add to dashboard Cite

Photoreceptors (PRs), as the most abundant and light-sensing cells of the neuroretina, are responsible for converting light into electrical signals that can be interpreted by the brain. PR degeneration, including morphological and functional impairment of these cells, causes significant diminution of the retina’s ability to detect light, with consequent loss of vision. Recent findings in ocular regenerative medicine have opened promising avenues to apply neuroprotective therapy, gene therapy, cell replacement therapy, and visual prostheses to the challenge of restoring vision. However, successful visual restoration in the clinical setting requires application of these therapeutic approaches at the appropriate stage of the retinal degeneration. In this review, firstly, we discuss the mechanisms of PR degeneration by focusing on the molecular mechanisms underlying cell death. Subsequently, innovations, recent developments, and promising treatments based on the stage of disorder progression are further explored. Then, the challenges to be addressed before implementation of these therapies in clinical practice are considered. Finally, potential solutions to overcome the current limitations of this growing research area are suggested. Overall, the majority of current treatment modalities are still at an early stage of development and require extensive additional studies, both pre-clinical and clinical, before full restoration of visual function in PR degeneration diseases can be realized. Graphical Abstract

show abstract